TABLE 1

Summary of Serogroup C Bactericidal Antibody Persistence as Determined by Serum Bactericidal Activity (SBA) 2–5 Years After Vaccination With Menveo and/or Menactra

Age Group (yrs) at VaccinationYears PostvaccinationSerogroup C SBAVaccineNo. of Vaccine Recipients in Study% of Recipients With Protective Antibody Levels
11 through 18*2% hSBA ““ 1:8Menveo27362
Menactra18558
11 through 183% hSBA ““ 1:4Menactra5235
MPSV44835
11 through 18§3% brSBA ““ 1:128Menactra7175
MPSV47260
2 through 10§5% brSBA ““ 1:128Menactra10855
MPSV420742
11 through 18§5% brSBA ““ 1:128Menactra1656
MPSV41060
  • Abbreviations: hSBA-SBA using human complement; brSBA-SBA using baby rabbit complement; MPSV4-quadrivalent meningococcal polysaccharide vaccine.

  • * Source: Gill C, Baxter R, Anemona A, Cavarro G, Dull P. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo) or Menactra among healthy adolescents. Human Vaccines; 2010, 6:881–7.

  • Source: Vu DM, Welsch JA, Zuno-Mitchell P, Dela Cruz N, Granoff DM. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. J Infect Dis 2006;193:821–8.

  • § Source: Proceedings of the Advisory Committee on Immunization Practices (ACIP) meeting, June 2009.

  • Reproduced with permission from Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep. 2011;60(3):74.